Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: A new approach to gene therapy of HIV infection

被引:35
作者
Arya, SK
Gallo, RC
机构
[1] Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda
[2] Laboratory of Tumor Cell Biology, Building 37, National Cancer Institute, Bethesda, MD 20892-4255
[3] Institute of Human Virology, Univ. of Maryland Biotech. Institute, University of Maryland, Baltimore, MD 21201
关键词
AIDS; transcriptional downmodulation; mutational analysis; chimeric genomes; retroviral vectors;
D O I
10.1073/pnas.93.9.4486
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Human immunodeficiency virus (HIV) type 2, the second AIDS-associated human retrovirus, differs from HIV-1 in its natural history, infectivity, and pathogenicity, as Kell as in details of its genomic structure and molecular behavior. We report here that HIV-2 inhibits the replication of HIV-I at the molecular level. This inhibition was selective, dose-dependent, and nonreciprocal. The closely related simian immunodeficiency provirus also inhibited HIV-1. The selectivity of inhibition was shown by the observation that HIV-2 did not significantly downmodulate the expression of the unrelated murine leukemia virus; neither did the murine leukemia virus markedly affect HIV-1 or HIV-2 expression. Moreover, while HIV-2 potently inhibited HIV-I, the reverse did not happen, thus identifying Set another and remarkable difference between HIV-I and HIV-2. Mutational analysis of the HIV-1, genome suggested that the inhibition follows a complex pathway, possibly involving multiple genes and redundant mechanisms. Introduction of inactivating mutations into the structural and regulatory/accessory genes did not render the HIV-2 provirus ineffective. Some of the HIV-2 gene defects, such as that of tat and rev genes, were phenotypically transcomplemented by HIV-1. The HIV-2 proviruses,vith deletions in the putative packaging signal and defective for virus replication were effective in inducing the suppressive phenotype. Though the exact mechanism remains to be defined, the inhibition appeared to be mainly due to an intracellular molecular event because it could not be explained solely on the basis of cell surface receptor mediated interference. The results support the notion that the inhibition likely occurred at the level of viral RNA, possibly involving competition between viral RNAs for some transcriptional factor essential for virus replication. Induction of a cytokine is another possibility. These findings might be relevant to the clinical-epidemiological data suggesting that infection with HIV-2 may offer some protection against HIV-1 infection.
引用
收藏
页码:4486 / 4491
页数:6
相关论文
共 32 条
  • [21] ENVELOPE GLYCOPROTEINS FROM BIOLOGICALLY DIVERSE ISOLATES OF IMMUNODEFICIENCY VIRUSES HAVE WIDELY DIFFERENT AFFINITIES FOR CD4
    IVEYHOYLE, M
    CULP, JS
    CHAIKIN, MA
    HELLMIG, BD
    MATTHEWS, TJ
    SWEET, RW
    ROSENBERG, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (02) : 512 - 516
  • [22] SLOWER HETEROSEXUAL SPREAD OF HIV-2 THAN HIV-1
    KANKI, PJ
    TRAVERS, KU
    MBOUP, S
    HSIEH, CC
    MARLINK, RG
    GUEYENDIAYE, A
    SIBY, T
    THIOR, I
    HERNANDEZAVILA, M
    SANKALE, JL
    NDOYE, I
    ESSEX, ME
    [J]. LANCET, 1994, 343 (8903) : 943 - 946
  • [23] KANKI PJ, 1994, AIDS, V8, P585
  • [24] MOLECULAR CHARACTERIZATION OF AN ATTENUATED HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 ISOLATE
    KUMAR, P
    HUI, HX
    KAPPES, JC
    HAGGARTY, BS
    HOXIE, JA
    ARYA, SK
    SHAW, GM
    HAHN, BH
    [J]. JOURNAL OF VIROLOGY, 1990, 64 (02) : 890 - 901
  • [25] HIV-1 TAT PROTEIN TRANS-ACTIVATES TRANSCRIPTION INVITRO
    MARCINIAK, RA
    CALNAN, BJ
    FRANKEL, AD
    SHARP, PA
    [J]. CELL, 1990, 63 (04) : 791 - 802
  • [26] REDUCED RATE OF DISEASE DEVELOPMENT AFTER HIV-2 INFECTION AS COMPARED TO HIV-1
    MARLINK, R
    KANKI, P
    THIOR, I
    TRAVERS, K
    EISEN, G
    SIBY, T
    TRAORE, I
    HSIEH, CC
    DIA, MC
    GUEYE, E
    HELLINGER, J
    GUEYENDIAYE, A
    SANKALE, JL
    NDOYE, I
    MBOUP, S
    ESSEX, M
    [J]. SCIENCE, 1994, 265 (5178) : 1587 - 1590
  • [27] CLINICAL, HEMATOLOGIC, AND IMMUNOLOGICAL CROSS-SECTIONAL EVALUATION OF INDIVIDUALS EXPOSED TO HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 (HIV-2)
    MARLINK, RG
    RICARD, D
    MBOUP, S
    KANKI, PJ
    ROMETLEMONNE, JL
    NDOYE, I
    DIOP, K
    SIMPSON, MA
    GRECO, F
    CHOU, MJ
    DEGRUTTOLA, V
    HSIEH, CC
    BOYE, C
    BARIN, F
    DENIS, F
    MCLANE, MF
    ESSEX, M
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1988, 4 (02) : 137 - 148
  • [28] LONG-TERM PROTECTION AGAINST SIV-INDUCED DISEASE IN MACAQUES VACCINATED WITH A LIVE ATTENUATED HIV-2 VACCINE
    PUTKONEN, P
    WALTHER, L
    ZHANG, YJ
    LI, SL
    NILSSON, C
    ALBERT, J
    BIBERFELD, P
    THORSTENSSON, R
    BIBERFELD, G
    [J]. NATURE MEDICINE, 1995, 1 (09) : 914 - 918
  • [29] MIXED HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN AN INDIVIDUAL - DEMONSTRATION OF BOTH HIV TYPE-1 AND TYPE-2 PROVIRAL SEQUENCES BY USING POLYMERASE CHAIN-REACTION
    RAYFIELD, M
    DECOCK, K
    HEYWARD, W
    GOLDSTEIN, L
    KREBS, J
    KWOK, S
    LEE, S
    MCCORMICK, J
    MOREAU, JM
    ODEHOURI, K
    SCHOCHETMAN, G
    SNINSKY, J
    OU, CY
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (06) : 1170 - 1176
  • [30] CELLULAR AND PLASMA VIRAL LOAD IN PATIENTS INFECTED WITH HIV-2
    SIMON, F
    MATHERON, S
    TAMALET, C
    LOUSSERTAJAKA, I
    BARTCZAK, S
    PEPIN, JM
    DHIVER, C
    GAMBA, E
    ELBIM, C
    GASTAUT, JA
    SAIMOT, AG
    BRUNVEZINET, F
    [J]. AIDS, 1993, 7 (11) : 1411 - 1417